GO:1903190 glyoxal catabolic process: Detoxification Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903190 (glyoxal catabolic process) describes the biochemical breakdown of glyoxal, a reactive dicarbonyl that forms advanced glycation endproducts (AGEs) and contributes to carbonyl stress.
• Glyoxal is generated endogenously from lipid peroxidation, glucose autoxidation, and exogenous sources such as food and electronic cigarette vapor.
• The catabolic process relies on enzymes including glyoxalase I (GLO1), glyoxalase II (GLO2), and aldehyde dehydrogenases, which convert glyoxal to glycolate or other less reactive metabolites.
• Dysregulated glyoxal catabolism is linked to diabetic complications, cardiovascular disease, multiple sclerosis, and cancer.
• Studying this process requires models that can isolate enzymatic steps, measure glyoxal flux, and assess downstream AGE formation.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of genes in the glyoxal catabolic pathway.
Description
Glyoxal (GO:1903190) is a highly reactive alpha-oxoaldehyde that arises from multiple metabolic and environmental sources, including glucose autoxidation, lipid peroxidation, and dietary intake. Because glyoxal readily modifies proteins, nucleic acids, and lipids, it is a major precursor of advanced glycation endproducts (AGEs) and a key contributor to carbonyl stress. The Gene Ontology term glyoxal catabolic process (GO:1903190) refers to the chemical reactions and pathways that result in the breakdown of glyoxal, thereby limiting its accumulation and toxicity. Understanding this catabolic process is essential for researchers studying diabetes, cardiovascular disease, neurodegeneration, and cancer, where glyoxal and related dicarbonyls have been implicated in disease progression. The pathway also intersects with redox biology, as ascorbate autoxidation and other oxidative processes can generate glyoxal and influence its detoxification. This article synthesizes current knowledge on the enzymatic steps, key genes, regulatory mechanisms, and experimental models used to investigate glyoxal catabolism, with a focus on how CRISPR-based approaches can accelerate discovery in this field.
glyoxal catabolic process At A Glance
| GO ID | GO:1903190 |
|---|---|
| GO term | glyoxal catabolic process |
| Ontology | biological_process |
| Synonym | glyoxal breakdown, glyoxal catabolism, glyoxal degradation |
| Major function | Breakdown of glyoxal to limit advanced glycation endproduct formation and carbonyl stress |
| Related enzymes | Glyoxalase I (GLO1), glyoxalase II (GLO2), aldehyde dehydrogenases |
| Associated diseases | Diabetic complications, cardiovascular disease, multiple sclerosis, cancer |
| Research methods | CRISPR knockout/knock-in, metabolomics, proteomics, enzyme assays |
What Is GO:1903190?
The glyoxal catabolic process (GO:1903190) is defined as the set of chemical reactions and pathways that result in the breakdown of glyoxal, a reactive dicarbonyl compound. This process encompasses enzymatic conversions that transform glyoxal into less reactive metabolites, such as glycolate, and thereby reduce its ability to form advanced glycation endproducts and cause cellular damage.
Why Is glyoxal catabolic process Important in Cell Biology?
Glyoxal catabolic process is critically important because glyoxal is a potent glycating agent that contributes to the formation of advanced glycation endproducts (AGEs), which are implicated in the pathogenesis of diabetic complications, cardiovascular disease, and neurodegenerative disorders. Efficient catabolism of glyoxal prevents the accumulation of these toxic metabolites and maintains cellular homeostasis. Moreover, glyoxal and its catabolic pathway are emerging as modulators of cancer metabolism and immune responses, making this process a potential therapeutic target. Understanding the regulation and genetic determinants of glyoxal catabolism can inform strategies to mitigate carbonyl stress in human disease.
• Glyoxal is a major precursor of advanced glycation endproducts (AGEs), which are linked to diabetic nephropathy, retinopathy, and neuropathy.
• Impaired glyoxal catabolism contributes to carbonyl stress in acute coronary syndrome and other cardiovascular conditions.
• Methylglyoxal, a related dicarbonyl, and its detoxification pathways are implicated in multiple sclerosis pathology.
• Glyoxal metabolism influences cancer cell survival and proliferation, suggesting a role in tumorigenesis.
• Dietary and environmental exposure to glyoxal (e.g., from chocolate, electronic cigarettes) can overwhelm endogenous detoxification.
• The pathway intersects with redox homeostasis, as ascorbate autoxidation can generate glyoxal and modulate its catabolism.
• Genetic variation in glyoxalase enzymes affects individual susceptibility to carbonyl stress-related diseases.
• Targeting glyoxal catabolic enzymes may offer therapeutic opportunities for AGE-related disorders.
• CRISPR screens can identify novel regulators of glyoxal catabolism, accelerating drug target discovery.
• Biomarkers of glyoxal catabolism (e.g., glycolate, AGEs) are useful for monitoring disease progression and treatment efficacy.
What Happens During glyoxal catabolic process?
Initial detoxification by the glyoxalase system
In simple terms: The glyoxalase system is the main route for removing glyoxal by converting it into a less harmful compound.
The glyoxalase system, comprising glyoxalase I (GLO1) and glyoxalase II (GLO2), catalyzes the conversion of glyoxal to S-D-lactoylglutathione and then to D-lactate. GLO1 uses glutathione as a cofactor to form the hemithioacetal intermediate, which rearranges to S-D-lactoylglutathione; GLO2 then hydrolyzes this intermediate to D-lactate and regenerates glutathione. This pathway is highly conserved and represents the primary route for glyoxal detoxification in cells.
Alternative oxidation by aldehyde dehydrogenases
In simple terms: Other enzymes can also break down glyoxal by oxidizing it to glycolate.
Aldehyde dehydrogenases (ALDHs), particularly ALDH2 and ALDH3A1, can oxidize glyoxal to glycolate, providing an alternative catabolic route. This oxidation reduces the pool of glyoxal available for glycation reactions and is especially relevant in tissues with high ALDH activity, such as the liver. The relative contribution of the glyoxalase system versus ALDH-mediated oxidation may vary by tissue and metabolic state.
Reductive conversion to glycolaldehyde
In simple terms: Glyoxal can also be reduced to glycolaldehyde, which can be further metabolized.
Reductases such as aldose reductase (AKR1B1) can reduce glyoxal to glycolaldehyde, which is then converted to glycolate or other metabolites. This reductive pathway may serve as a minor route for glyoxal clearance, particularly under conditions of high oxidative stress. The interplay between oxidative and reductive catabolic routes influences the overall detoxification capacity.
Downstream metabolism of catabolic products
In simple terms: The products of glyoxal breakdown, like D-lactate and glycolate, enter central metabolic pathways.
D-lactate produced by the glyoxalase system can be converted to pyruvate by D-2-hydroxyacid dehydrogenase, feeding into gluconeogenesis or the tricarboxylic acid cycle. Glycolate can be oxidized to glyoxylate and then to oxalate or glycine, linking glyoxal catabolism to amino acid and energy metabolism. These downstream steps ensure that carbon from glyoxal is either recycled or excreted.
Regulation by glutathione availability
In simple terms: The glyoxalase system depends on glutathione, so cellular glutathione levels control how fast glyoxal is broken down.
Glutathione (GSH) is an essential cofactor for GLO1 and GLO2. Changes in GSH synthesis or redox status directly affect glyoxalase activity and thus the rate of glyoxal catabolism. Oxidative stress can deplete GSH, impairing glyoxal clearance and exacerbating carbonyl stress. Therefore, the glyoxal catabolic process is tightly linked to cellular antioxidant capacity.
Key Genes Involved in GO:1903190 glyoxal catabolic process
The following genes encode enzymes and regulators directly involved in the glyoxal catabolic process, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GLO1 | Glyoxalase I; converts glyoxal to S-D-lactoylglutathione | Central enzyme in glyoxal detoxification; target for cancer and diabetes studies |
| GLO2 | Glyoxalase II; hydrolyzes S-D-lactoylglutathione to D-lactate | Completes the glyoxalase pathway; mutations linked to metabolic disorders |
| ALDH2 | Aldehyde dehydrogenase 2; oxidizes glyoxal to glycolate | Mitochondrial aldehyde dehydrogenase; involved in alcohol metabolism and cardioprotection |
| ALDH3A1 | Aldehyde dehydrogenase 3A1; oxidizes glyoxal to glycolate | Cytosolic enzyme with high activity toward glyoxal; protects against oxidative stress |
| AKR1B1 | Aldose reductase; reduces glyoxal to glycolaldehyde | Polyol pathway enzyme; implicated in diabetic complications |
| G6PD | Glucose-6-phosphate dehydrogenase; maintains NADPH for GSH regeneration | Supports glyoxalase system by providing reducing equivalents |
| GCLC | Glutamate-cysteine ligase catalytic subunit; rate-limiting for GSH synthesis | Regulates glutathione availability for glyoxalase I and II |
| GCLM | Glutamate-cysteine ligase modifier subunit; regulates GSH synthesis | Modulates glyoxal catabolism via glutathione pool |
| GSS | Glutathione synthetase; synthesizes glutathione | Essential for glyoxalase cofactor supply |
| GSR | Glutathione reductase; regenerates GSH from GSSG | Maintains reduced glutathione for glyoxalase activity |
| TXN | Thioredoxin; reduces oxidized proteins | Indirectly supports glyoxal catabolism by maintaining redox balance |
| TXN2 | Thioredoxin 2; mitochondrial thioredoxin | Protects mitochondrial enzymes from glyoxal-induced damage |
| PRDX1 | Peroxiredoxin 1; reduces peroxides | Limits oxidative stress that generates glyoxal |
| SOD1 | Superoxide dismutase 1; detoxifies superoxide | Reduces glyoxal formation from oxidative stress |
| CAT | Catalase; decomposes hydrogen peroxide | Prevents glyoxal generation via Fenton chemistry |
| NQO1 | NAD(P)H quinone dehydrogenase 1; antioxidant enzyme | May influence glyoxal catabolism through redox regulation |
How Is glyoxal catabolic process Regulated?
The glyoxal catabolic process is regulated at multiple levels. Transcriptional regulation of GLO1 and GLO2 can be influenced by stress-responsive transcription factors such as Nrf2, which coordinates antioxidant defense. Post-translational modifications, including phosphorylation and acetylation, may modulate enzyme activity. Additionally, the availability of glutathione, controlled by GCLC, GCLM, GSS, and GSR, directly limits glyoxalase flux. Hormonal and metabolic signals, such as insulin and glucagon, can affect glyoxal metabolism indirectly by altering glucose flux and oxidative stress. In cancer cells, oncogenic signaling pathways (e.g., PI3K/Akt) may upregulate GLO1 to support proliferation and survival under metabolic stress. Thus, glyoxal catabolism is integrated with cellular redox, metabolic, and stress-response networks.
glyoxal catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GLO1 | Diabetes complications, cancer | GLO1 knockout and overexpression cell lines; mouse models of diabetes |
| GLO2 | Metabolic disorders, neuropathy | GLO2 knockout iPSCs; enzymatic activity assays |
| ALDH2 | Cardiovascular disease, alcohol sensitivity | ALDH2*2 knock-in mice; patient-derived cells |
| AKR1B1 | Diabetic retinopathy, nephropathy | AKR1B1 knockout mice; aldose reductase inhibitors |
| G6PD | Oxidative stress-related diseases | G6PD-deficient cells; CRISPR correction |
Glyoxal catabolism in diabetes and cardiovascular disease
In diabetes, chronic hyperglycemia increases glyoxal formation from glucose autoxidation and lipid peroxidation, overwhelming catabolic capacity and leading to AGE accumulation. Elevated glyoxal and AGEs contribute to endothelial dysfunction, atherosclerosis, and nephropathy. Patients with acute coronary syndrome show increased carbonyl stress, and glyoxal catabolic enzymes are potential biomarkers. Enhancing glyoxal detoxification may reduce cardiovascular complications.
Glyoxal catabolism in multiple sclerosis
Methylglyoxal, a close relative of glyoxal, and its derived AGEs have been implicated in the pathogenesis of multiple sclerosis. Dysregulated glyoxalase activity may contribute to neuroinflammation and demyelination. Targeting the glyoxal catabolic pathway could offer neuroprotective strategies.
Glyoxal catabolism in cancer
Cancer cells often exhibit altered glyoxal metabolism. Upregulation of GLO1 is observed in many tumors and supports detoxification of methylglyoxal, a byproduct of glycolysis, thereby promoting cell survival. Conversely, excessive glyoxal can induce apoptosis, making glyoxal catabolic enzymes attractive targets for anticancer therapy. Modulating this pathway may sensitize tumors to chemotherapy.
Glyoxal catabolism in food and environmental health
Dietary glyoxal from foods such as chocolate and beverages, as well as from electronic cigarette vapor, can contribute to total body glyoxal load. Understanding how the catabolic process handles exogenous glyoxal is important for assessing health risks and developing mitigation strategies.
From glyoxal catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GLO1 loss impair glyoxal clearance? | GLO1 knockout cell lines (e.g., HEK293, HeLa) |
| Does a specific GLO1 polymorphism affect enzyme activity? | Point-mutation knock-in via CRISPR |
| Can tagged GLO1 be used to track subcellular localization? | Knock-in of fluorescent tag (e.g., GFP) at GLO1 locus |
| Does GLO1 overexpression protect against glyoxal-induced toxicity? | GLO1 overexpression stable cell lines |
| What genes regulate glyoxal catabolism? | Genome-wide CRISPR knockout library screening |
| Can glyoxal catabolism be monitored in live cells? | Genetically encoded glyoxal biosensors (knock-in) |
How to Study the glyoxal catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Glyoxal, glycolate, D-lactate levels | Quantifying pathway flux in cells and tissues |
| Enzyme activity assay | GLO1, GLO2, ALDH activity | Validating knockout/overexpression models |
| Western blot | Protein expression of GLO1, GLO2, etc. | Assessing genetic manipulation efficiency |
| CRISPR screen | Gene essentiality for glyoxal tolerance | Discovery of novel regulators |
| Glycation ELISA | AGE levels (e.g., CML, MG-H1) | Linking catabolism to disease markers |
| Fluorescent biosensor imaging | Real-time glyoxal levels | Live-cell dynamics of catabolism |
| RNA-seq | Transcriptional changes in catabolic genes | Identifying regulatory networks |
| Proteomics | Glycated protein profiles | Mapping downstream damage |
Metabolomics and flux analysis
Liquid chromatography-mass spectrometry (LC-MS) can quantify glyoxal, glycolate, D-lactate, and other metabolites to assess catabolic flux. Isotope tracing with 13C-labeled glucose or glyoxal precursors enables dynamic measurement of pathway activity.
Enzymatic activity assays
Glyoxalase I and II activities can be measured spectrophotometrically by monitoring the formation of S-D-lactoylglutathione or D-lactate. Aldehyde dehydrogenase activity can be assayed using NAD+ reduction. These assays are useful for validating genetic models.
Proteomics and glycation profiling
Mass spectrometry-based proteomics can identify protein targets of glyoxal glycation and quantify AGEs. This helps link glyoxal catabolism to cellular damage and disease markers.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that modulate glyoxal tolerance or catabolic flux. Coupled with next-generation sequencing, these screens reveal novel regulators of the pathway.
How CRISPR Can Be Used to Study GO:1903190 glyoxal catabolic process
Knockout
CRISPR knockout of GLO1, GLO2, or ALDH2 in cell lines can abolish specific catabolic steps, leading to glyoxal accumulation and increased AGE formation. These models are valuable for studying the consequences of impaired detoxification and for testing compensatory pathways.
Point Mutation
Introducing disease-associated point mutations (e.g., GLO1 SNPs) via CRISPR base editing or homology-directed repair allows researchers to dissect the impact of specific variants on enzyme activity and glyoxal clearance. This is particularly useful for understanding genetic susceptibility to diabetic complications.
Knock-in
Knock-in of epitope tags (e.g., FLAG, GFP) at endogenous GLO1 or GLO2 loci enables real-time tracking of protein localization, interaction, and turnover without overexpression artifacts. This approach can reveal subcellular sites of glyoxal catabolism.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of GLO1 can boost glyoxal catabolic capacity, protecting cells from glyoxal-induced toxicity. Such models are useful for testing therapeutic potential of enhancing detoxification.
How EDITGENE Supports glyoxal catabolic process Research
Researchers studying glyoxal catabolic process-related genes often need to determine whether a candidate gene is causally involved in glyoxal detoxification, how specific mutations affect enzyme function, and whether modulating the pathway can alter disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for glyoxal catabolic process research.
Frequently Asked Questions About glyoxal catabolic process
What is glyoxal catabolic process (GO:1903190)?
It is the set of biochemical reactions that break down glyoxal, a reactive dicarbonyl, into less harmful metabolites such as D-lactate and glycolate.
What genes are involved in glyoxal catabolic process?
Key genes include GLO1, GLO2, ALDH2, ALDH3A1, and AKR1B1, which encode enzymes that directly metabolize glyoxal.
How is glyoxal catabolism linked to diabetes?
In diabetes, high glucose increases glyoxal formation, overwhelming catabolic capacity and leading to advanced glycation endproducts that damage tissues.
What is the role of GLO1 in glyoxal detoxification?
GLO1 (glyoxalase I) catalyzes the first step of the glyoxalase system, converting glyoxal to S-D-lactoylglutathione using glutathione as a cofactor.
Can CRISPR be used to study glyoxal catabolic process?
Yes, CRISPR knockout, knock-in, and overexpression models allow researchers to test the causal role of specific genes in glyoxal metabolism.
What diseases are associated with impaired glyoxal catabolism?
Impaired glyoxal catabolism is linked to diabetic complications, cardiovascular disease, multiple sclerosis, and cancer.
How is glyoxal catabolic process measured experimentally?
It can be measured using LC-MS metabolomics, enzyme activity assays, and glycation profiling to quantify glyoxal and its metabolites.
What are the products of glyoxal catabolism?
The main products are D-lactate and glycolate, which can enter central metabolic pathways.
Is glyoxal catabolism regulated by glutathione?
Yes, glutathione is an essential cofactor for glyoxalase enzymes, so cellular glutathione levels directly affect the rate of glyoxal breakdown.
How can EDITGENE help with glyoxal catabolic process research?
EDITGENE offers custom CRISPR knockout, knock-in, overexpression, and library screening services to study genes involved in glyoxal catabolism.
Conclusion
The glyoxal catabolic process (GO:1903190) is a critical metabolic pathway that protects cells from the toxic effects of glyoxal, a reactive dicarbonyl implicated in diabetes, cardiovascular disease, neurodegeneration, and cancer. Understanding the enzymes, regulatory mechanisms, and genetic determinants of this pathway is essential for developing therapeutic strategies to mitigate carbonyl stress. CRISPR-based models provide powerful tools to dissect the causal roles of specific genes and to identify novel targets for intervention. EDITGENE's comprehensive services support researchers in advancing this important field.
References
- 1. Banerjee S et al.. 2014. Structural alterations of hemoglobin and myoglobin by glyoxal: a comparative study.. Int J Biol Macromol 66:311-8 PMID: 24613676
- 2. Bekki K et al.. 2014. Carbonyl compounds generated from electronic cigarettes.. Int J Environ Res Public Health 11(11):11192-200 PMID: 25353061
- 3. Zhang M et al.. 2024. Glyoxal in Foods: Formation, Metabolism, Health Hazards, and Its Control Strategies.. J Agric Food Chem 72(5):2434-2450 PMID: 38284798
- 4. Wetzels S et al.. 2017. Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.. Int J Mol Sci 18(2) PMID: 28212304
- 5. Ede-Cintesun E et al.. 2024. Glyoxal and methylglyoxal formation in chocolate and their bioaccessibility.. Food Res Int 189:114552 PMID: 38876591
- 6. Yoshitake J et al.. 2022. Autoxidation of ascorbate mediates lysine N-pyrrolation.. Free Radic Res 56(11-12):749-759 PMID: 36725333
- 7. Alfarouk KO et al.. 2021. The possible role of methylglyoxal metabolism in cancer.. J Enzyme Inhib Med Chem 36(1):2010-2015 PMID: 34517737
- 8. Bora S et al.. 2021. Carbonyl stress in diabetics with acute coronary syndrome.. Clin Chim Acta 520:78-86 PMID: 34090879
